Introduction
Lung cancer is the leading cause of cancer-related deaths worldwide [1] . Mutations in tumor suppressor genes are known to play key roles in the progression of lung cancer. LKB1, the causative gene for Peutz-Jeghers syndrome characterized by gastrointestinal polyposis, is frequently mutated in lung adenocarcinomas [2] . LKB1 possesses a variety of tumor-suppressive functions, such as cell polarity regulation, cell cycle arrest, induction of apoptosis and inhibition of cell growth [3, 4] . LKB1 encodes a serine/threonine protein kinase that directly activates the protein that senses intracellular ATP levels-AMP-activated protein kinase (AMPK). AMPK then phosphorylates tuberin protein (TSC2) to turn on its GTPactivating protein activity to inhibit the protein Ras homolog enriched in brain (Rheb), which inhibits mammalian target of rapamycin (mTOR) signaling [5] . Thus, LKB1/AMPK negatively regulates mTOR activity. mTOR is at the center of cell growth and proliferation. It acts as a scaffold to recruit the downstream substrates eukaryotic initiating factor 4E Binding Protein 1 (4EBP1) and ribosomal S6 kinase (p70S6K1) [6] . Rapamycin is the first specific mTOR inhibitor to be characterized. However, its poor aqueous solubility and chemical stability restricts its application in clinical cancer therapy. Hence, a variety of rapamycin analogs (termed rapalogs) have been developed, including RAD001 (everolimus) and CCI-779 (temsirolimus) among others [7] . Previous studies have shown that rapalogs are effective in certain types of tumors [8, 9] , and approximately 26% of cancers are sensitive to mTOR inhibition [10] . It is conceivable that various genetic backgrounds might contribute different responses to mTOR inhibition.
Because LKB1 negatively regulates mTOR activity, it is speculated that LKB1 inactivation may lead to the hyperactivation of mTOR and result in increased sensitivity to mTOR inhibitors. Accordingly, LKB1-inactivated endometrial cancers have been shown to be highly responsive to mTOR inhibition [11] . Therefore, LKB1 deficiency in tumors appears to be a predictive for good clinical responses to mTOR inhibitors. How-www.nature.com/aps Xiao P et al Acta Pharmacologica Sinica npg ever, in the present study, we found that LKB1 inactivation in NSCLC cells did not increase sensitivity to mTOR inhibitors. In addition, we show that mTOR inhibition induces negative feedback activation of AKT in a PI3K-dependent manner, which possibly contributes to the mTOR inhibitor resistance.
Materials and methods

Materials
Antibodies against phospho-S6K-Thr389, phospho-4EBP-Ser65, phospho-AKT, AKT, 4EBP1, and S6K were purchased from Cell Signaling Technology (Beverly, MA, USA). Mouse anti-GAPDH antibody was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Rapamycin, RAD001 (everolimus, an allosteric mTOR inhibitor) and LY294002 were purchased from LC Laboratories (Boston, MA, USA). Sulforhodamine B (SRB) was purchased from Sigma-Aldrich (St Louis, MO, USA).
Cell lines and cell culture
Five lung cancer cell lines: Calu-1, H460, H1299, H1792, and A549 were purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA). LKB1 stable knock down cell line H1299-LKB1shRNA and control cell line H1299-PLKO.1 were established in our lab [12] . Cells were cultured in RPMI-1640 medium (Gibco, Grand Island, NY, USA) supplemented with 10% fetal bovine serum (Gibco) at 37 °C in a humidified atmosphere with 5% CO 2 .
Western blotting
Proteins were resolved by polyacrylamide gel electrophoresis and transferred onto polyvinylidene difluoride (PVDF) membranes (Millipore, Germany). The membranes were blocked in Tris-buffered saline containing 0.2% Tween 20 and 5% fat-free dry milk and incubated first with primary antibodies and then with horseradish peroxidase-conjugated secondary antibodies. Specific proteins were visualized with enhanced chemiluminescence detection reagent according to the manufacturer's instructions (Pierce Biotechnology, Waltham, MA, USA).
MTS assay
Cells grown in 96-well culture plates were treated with a gradient of concentrations of rapamycin or RAD001 for 72 h. Cell growth inhibition was determined with the Cell Titer 96 Aqueous Non-Radioactive Cell Proliferation Assay (Promega, Fitchburg, WI, USA) according to the manufacturer's instructions.
SRB assay
Cells grown in 96-well culture plates were treated with a gradient of concentrations of rapamycin or RAD001 for 72 h, fixed with 10% trichloroacetic acid and stained with 0.4% SRB dissolved in 1% acetic acid. The cells were then washed with 1% acetic acid to remove unbound dye. The protein-bound dye was extracted with 10 mmol/L Tris base to determine the optical density at a wavelength of 490 nm. The percentage of cell proliferation as a function of drug concentration was plotted to determine the IC 50 , which represents the drug concentration needed for 50% inhibition of cell proliferation.
Statistical analysis SPSS (Statistical Package for the Social Sciences) software version 17 (IBM Corporation, NY, USA) was used for statistical analysis of the experimental results. Most of our results were represented by at least three independent experiments and are presented as the mean±standard deviation (SD) of triplicate samples. Error bars represent standard deviations between experiments.
One-way analysis of variance and Student's t-test were used to determine statistical significance. P<0.05 was considered statistically significant.
Results
LKB1 mutant NSCLC cells displayed higher mTOR activity
According to previous studies, the cell lines H460 and A549 have a nonsense LKB1 mutation at codon 37, whereas H1792 and Calu-1 possess wild-type LKB1 [13] . LKB1 has been reported to negatively regulate mTOR activity; thus, we sought to compare the basal level of mTOR activity in various NSCLC cells with or without LKB1 inactivation. As shown in Figure 1 , we found that LKB1 mutant cells (H460 and A549) displayed mTOR activity that was higher than in LKB1 wildtype cells (H1792 and Calu-1), as demonstrated by increased phosphorylation of S6K and 4EBP1, the two main substrates downstream of mTOR.
LKB1 inactivation does not increase the sensitivity to mTOR inhibitors mTOR is a key regulator of cell growth; thus, we hypothesized (Figure 2A ), confirming the inhibition of mTOR activity by rapamycin in NSCLC cells. We then treated these cells with a gradient of concentrations of rapamycin and measured cell proliferation by MTS assay. Unexpectedly, rapamycin had little effect on the growth of either H1299 (wild-type LKB1) or H460 (mutant LKB1) cells ( Figure 2B ). To validate our observation, we used the mTOR specific inhibitor RAD001.
As shown in Figure 2C , treatment of A549 cells with a gradient of concentrations of RAD001 determined that RAD001 decreased 4EBP1 phosphorylation in a dose-dependent manner, indicating that it effectively inhibited mTOR activity. Next, we examined its effect on cell proliferation with MTS assay. Similarly to rapamycin, RAD001 did not obviously affect the proliferation of the various NSCLC cell lines ( Figure  2D ). Growth inhibition by RAD001, even at concentrations up to 1000 nmol/L, was less than 50%. Moreover, some LKB1 wild-type cells, such as Calu-1, were even more responsive to RAD001 than the LKB1 mutant cells, including H460. To confirm our results, we additionally measured cell proliferation by SRB assays, and similar results were achieved ( Figure 2E ). Thus, no association was found between sensitivity to mTOR inhibitors and LKB1 gene status.
To further verify our findings, we established the isogenic cell lines H1299-LKB1shRNA and H1299-PLKO.1 using a lentiviral short hairpin RNA against LKB1 [12] . As shown in Figure 2F , LKB1 protein expression was significantly decreased in H1299-LKB1shRNA cells. We next examined the effect of rapamycin and RAD001 on the proliferation of H1299-LKB1shRNA and H1299-PLKO.1 cells. As shown in Figure 2G and 2H, stable knockdown of LKB1 did not significantly influence the growth inhibition induced by rapamycin or RAD001. Taken together, these data suggest that NSCLC cells are resistant to mTOR inhibitors and that LKB1 inactivation does not increase their sensitivity. mTOR inhibition induces AKT activation in a PI3K-dependent manner We next sought to examine the molecular mechanism underlying the resistance to mTOR inhibition in NSCLC cells with or without LKB1 inactivation. Because AKT signaling is known to be a major survival pathway, we examined the potential involvement of AKT activation in RAD001 treatment. NSCLC cells (H1792, Calu-1, A549, and H460) were treated with RAD001 (10 nmol/L) for 2 h, and p-AKT was analyzed by Western blot. It was observed that RAD001 treatment led to a significant increase in p-AKT, suggesting that mTOR inhibition induced AKT activation ( Figure 3A) .
PI3K is the primary upstream regulator of AKT. To investigate whether PI3K is involved in RAD001-induced AKT activation, we treated H1792 and A549 cells with RAD001 (10 nmol/L) as a single agent or in combination with LY294002 (PI3K inhibitor, 10 µmol/L) for 2 h, and p-AKT was analyzed by Western blot. We found that the combination of RAD001 with LY294002 attenuated the phosphorylation of AKT relative to the RAD001 alone treated group ( Figure 3B ). These data suggest that PI3K is involved in RAD001-induced AKT activation.
Combination treatment with RAD001 and LY294002 enhances the antitumor effects. Because PI3K is required for RAD001-induced activation of AKT, we speculated that PI3K inhibition by LY294002 combined with RAD001 might increase growth inhibition. To investigate this possibility, H1792 and A549 cells were treated with RAD001 alone or in combination with LY294002 for 72 h, and MTS assays were performed. As expected, the combination of RAD001 and LY294002 enhanced the antitumor effects ( Figure 4A, 4B ).
Discussion
A powerful approach to cancer therapy is to suppress oncogenic signaling using molecular-target inhibitors. RAD001 has been approved for the treatment of advanced renal carcinoma, pancreatic neuroendocrine cancers and certain cancers associated with hereditary tuberous sclerosis [14] . However, clinical trials indicate that RAD001 has only moderate antitumor efficacy [15, 16] , and there remains an urgent need to identify predictive markers for selecting patients who will significantly benefit from treatment with rapalogs. Several studies have revealed that the PI3K/AKT/PTEN status might not be predictive of the rapalog response [17] . Shackelford found that rapamycin monotherapy decreased polyp burden and size in LKB1 +/-mice with polyposis [18] . In addition, endometrial cancers with LKB1 inactivation are highly responsive to mTOR inhibitors [11] , which led us to speculate that LKB1 may be a predictor of response to rapalogs. However, in the present study, we found that NSCLC cells are insensitive to rapamycin or RAD001 by both MTS and SRB assays, and the cellular response to mTOR inhibitors has no association with LKB1 gene status. Thus, LKB1 is not an appropriate predictor in NSCLC cell lines. As the signaling network of mTOR is quite complex, investigating additional biomarkers will be necessary in the future.
Previous studies have shown that rapamycin leads to a marked increase in AKT activity in MCF-7 (breast cancer cell line), MDA-MB-468 (breast cancer cell line) and DU-145 (prostate cancer cell line) cells [19, 20] . Accordingly, we also found that mTOR inhibitors activate a negative feedback pathway, leading to activation of AKT, which might attenuate its anticancer effects. In addition, our data shows that the combined treatment of RAD001 with LY294002 decreased p-AKT, suggesting the involvement of PI3K in AKT activation induced by mTOR inhibition. This finding is in good agreement with a study showing that the inhibition of p70/S6K induced by rapamycin results in increased IGF-IR/IRS-1/PI3K signaling to phosphor- www.chinaphar.com Xiao P et al Acta Pharmacologica Sinica npg ylate AKT [19] . Thus, mTOR/PI3K dual inhibitors may synergistically inhibit tumorigenesis, as evidenced in our experiment. However, the precise mechanism by which an mTOR inhibitor induces AKT activation remains to be determined. It has been reported that rapamycin increases the expression of receptor tyrosine kinases, such as EGFR, HER2, and HER3, which might lead to feedback activation of AKT [21, 22] . Future studies are needed to clarify these questions.
In conclusion, our study demonstrates that LKB1 inactivation does not affect the cellular response to mTOR inhibitors in non-small cell lung cancer cells. In addition, we found that mTOR inhibitors induced negative feedback activation of AKT, which might contribute to the observed resistance.
